The products are NIXIT, an oral Nicotine Replacement Therapy (NRT), and JOINTFLEX, a topical analgesic cream for joint care.
At present, the NRT market is pegged at Rs 156 crore and projected to reach Rs 600 crore by 2023.
It is largely led by chewing gum format while SCPLs NIXIT has introduced the Lozenge format in India, company officials said.
According to company officials, JOINTFLEX has been in the US for over 20 years besides 15 other countries.
In India, it comes with an ayurvedic formulation, they added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)